地榆升白片联合重组人粒细胞刺激因子治疗癌症相关性乏力的临床分析  

Clinical analysis of Diyu Shengbai tablets combined with granulocyte colony stimulating factor in treatment of cancer related fatigue syndrome

作　　者：刘纯一[1] 胡新彦[1] 徐立霞[1] 孔雁[1] 刘风玲[1] 

机构地区：[1]河北医科大学第四医院肿瘤内科,河北石家庄050011

出　　处：《中国生化药物杂志》2015年第3期98-99,共2页Chinese Journal of Biochemical Pharmaceutics

基　　金：河北省科技支撑计划项目课题(11276161)

摘　　要：目的：探讨地榆升白片联合重组人粒细胞刺激因子治疗癌症相关性乏力的临床疗效。方法选择2011年1月～2013年12月在河北医科大学第四医院肿瘤内科收治的Ⅱ～Ⅵ期原发性癌症患者60例，将其随机分为2组，对照组30例，在化疗期间给予重组人粒细胞集落刺激因子；实验组30例，在对照组治疗基础上给予地榆升白片。结果化疗后，实验组患者出现乏力人数比率和白细胞下降人数比率均显著低于对照组，差异有统计学意义（ P＜0．05）。结论地榆升白片联合重组人粒细胞集落刺激因子在肿瘤患者化疗期间所致的白细胞减少和疲劳症状明显改善。Objective To analysis clinical effect of Diyu Shengbai tablets combined with granulocyte colony stimulating factor on cancer related fatigue syndrome.Methods II-VI primary cancer 60 patients from January 2011 to December 2013 were admitted to department of internal medicine, Fourth Hospital of Hebei Medical University,and randomly divided into two groups.Control goup（n=30）were treated with granulocyte colony stimulating factor（G-CSF）.Experimental group（n=30）were treated with Diyu Shengbai tablets and G-CSF.Results After chemotherapy, ratio of patients in the experimental group appeared fatigue syndrome and changes in leukocyte was significantly lower than that of control group, the difference was statistically significant （ P 〈0.05 ） . Conclusion Diyu Shengbai tablets combined with G-CSF have better clinical efficacy for leukopenia caused by tumor chemotherapy, the symptom of fatigue also can improve significantly.

关 键 词：地榆升白片 重组人粒细胞刺激因子 疲乏 

分 类 号：R973[医药卫生—药品]